Heron Therapeutics Q4 revenue dips as Acute Care segment holds fort
Overview
Biotechnology firm's Q4 2025 net revenue was $40.6 mln, slightly down yr/yr
Acute Care franchise revenue grew 57.3% yr/yr in Q4 2025
Company projects 2026 net revenue of $173 to $183 mln
Outlook
Heron expects 2026 net revenue between $173 mln and $183 mln
Company forecasts 2026 adjusted EBITDA between $10 mln and $20 mln
Heron cites improved reimbursement clarity as a factor for 2026 revenue growth
Result Drivers
ZYNRELEF ADOPTION - Enhanced distributor incentives and CMS approval of a product-specific J-Code accelerated ZYNRELEF adoption
APONVIE UTILIZATION - Inclusion in guidelines and dedicated sales team boosted APONVIE utilization
ACUTE CARE GROWTH - Strategic decisions led to 65% yr/yr net revenue growth in Acute Care franchise
Company press release: ID:nGNX6GzT8R
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Product Sales |
| $40.59 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Heron Therapeutics Inc is $4.00, about 270.4% above its February 25 closing price of $1.08
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Has Beating Expectations Become the Norm? Nvidia Delivers Strong Q4 Results Again, but Market Remains Cautious?
TradingKey - Nvidia (NVDA) reported fourth-quarter results on Wednesday that beat expectations across the board, with its core data center business revenue surging 75% year-over-year to become the primary growth engine.
Circle Stock Price Outlook: Will Circle Internet Group Rebound in 2026?
TradingKey - Circle Internet Group (CRCL) saw its stock price experience a roller coaster ride since its 2025 IPO debut at $31 a share. Those early fireworks faded, and the shares now sit roughly 75% below their June peak, though they’re still more than double the IPO level. Outside of that first-mo
Nvidia Q4 Earnings: Market Fears Competition, but NVDA Moat is Beyond CUDA
All eyes are on Nvidia this week, as the company reports its 2026Q4 earnings.
Nvidia Q4 Earnings Preview: AI-Driven Growth Versus Market Expectations
TradingKey - NVIDIA (NVDA) is set to release its fourth quarter fiscal year 2026 earnings report after the market close on February 25, ET. As the world undergoes a period of rapid AI technological advancement, market debates over a capital expenditure bubble have intensified. In this context, NVIDIA’s results serve not only as a test of its business performance but also as a core bellwether for the sustainability of the global AI boom.
